211 related articles for article (PubMed ID: 25672620)
1. Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells.
Somasagara RR; Deep G; Shrotriya S; Patel M; Agarwal C; Agarwal R
Int J Oncol; 2015 Apr; 46(4):1849-57. PubMed ID: 25672620
[TBL] [Abstract][Full Text] [Related]
2. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
3. Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells.
Dhar D; Deep G; Kumar S; Wempe MF; Raina K; Agarwal C; Agarwal R
Mol Carcinog; 2018 Sep; 57(9):1166-1180. PubMed ID: 29727019
[TBL] [Abstract][Full Text] [Related]
4. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
[TBL] [Abstract][Full Text] [Related]
6. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
7. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
[TBL] [Abstract][Full Text] [Related]
8. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells.
Amrutkar M; Aasrum M; Verbeke CS; Gladhaug IP
BMC Cancer; 2019 Jun; 19(1):596. PubMed ID: 31208372
[TBL] [Abstract][Full Text] [Related]
9. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
10. Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G
Peng T; Dou QP
J Cell Biochem; 2017 Sep; 118(9):2722-2730. PubMed ID: 28165150
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Fryer RA; Barlett B; Galustian C; Dalgleish AG
Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
[TBL] [Abstract][Full Text] [Related]
12. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
Li J; Liang X; Yang X
Oncol Rep; 2012 Aug; 28(2):501-10. PubMed ID: 22641480
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Shimasaki T; Ishigaki Y; Nakamura Y; Takata T; Nakaya N; Nakajima H; Sato I; Zhao X; Kitano A; Kawakami K; Tanaka T; Takegami T; Tomosugi N; Minamoto T; Motoo Y
J Gastroenterol; 2012 Mar; 47(3):321-33. PubMed ID: 22041920
[TBL] [Abstract][Full Text] [Related]
14. Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.
Yung MM; Ross FA; Hardie DG; Leung TH; Zhan J; Ngan HY; Chan DW
Integr Cancer Ther; 2016 Sep; 15(3):376-89. PubMed ID: 26487740
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
Funamizu N; Kamata Y; Misawa T; Uwagawa T; Lacy CR; Yanaga K; Manome Y
Pancreas; 2012 Jan; 41(1):107-13. PubMed ID: 21926937
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
Zhou HY; Yao XM; Chen XD; Tang JM; Qiao ZG; Wu XY
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10283-10289. PubMed ID: 31841183
[TBL] [Abstract][Full Text] [Related]
17. Differential modulation of nicotine-induced gemcitabine resistance by GABA receptor agonists in pancreatic cancer cell xenografts and in vitro.
Banerjee J; Al-Wadei HA; Al-Wadei MH; Dagnon K; Schuller HM
BMC Cancer; 2014 Sep; 14():725. PubMed ID: 25260978
[TBL] [Abstract][Full Text] [Related]
18. ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells.
Zheng C; Jiao X; Jiang Y; Sun S
J Int Med Res; 2013 Apr; 41(2):300-6. PubMed ID: 23569008
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
[TBL] [Abstract][Full Text] [Related]
20. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Hagmann W; Jesnowski R; Löhr JM
Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
